The biology and treatment of Merkel cell carcinoma: current understanding and research priorities.
The biology and treatment of Merkel cell carcinoma: current understanding and research priorities.
复制标题
DOI：
10.1038/s41571-018-0103-2
复制
发表时间：
2018-12
期刊：
影响因子：
--
通讯作者：
International Workshop on Merkel Cell Carcinoma Research (IWMCC) Working Group
中科院分区：
文献类型：
--
作者：
Harms PW;Harms KL;Moore PS;DeCaprio JA;Nghiem P;Wong MKK;Brownell I;International Workshop on Merkel Cell Carcinoma Research (IWMCC) Working Group
默克尔细胞癌（MCC）是一种罕见的侵袭性皮肤癌，与高龄和免疫抑制有关。在过去的十年中，人们发现MCC与默克尔细胞多瘤病毒的整合（可能导致肿瘤发生）或紫外线诱导的DNA损伤引起的体细胞突变之间存在关联。病毒阳性和病毒阴性的MCC都具有免疫原性，抑制程序性细胞死亡蛋白1 (PD-1) -程序性细胞死亡配体1 （PD-L1）免疫检查点已被证明在治疗转移性MCC患者中非常有效；然而，并非所有患者对免疫治疗都有持久的反应。尽管在对MCC患者的理解和管理方面取得了这些快速进展，但许多基础、转化和临床研究问题仍未得到解答。2018年3月，在美国国家癌症研究所举行了默克尔细胞癌研究国际研讨会，学术界、政府和行业专家齐聚一堂，确定了最优先的研究问题。在这里，我们回顾了MCC的生物学和治疗，并报告了研讨会上达成共识的建议。默克尔细胞癌（MCC）是一种罕见的侵袭性非黑色素瘤皮肤癌。免疫检查点抑制的可用性改善了一部分MCC患者的预后，尽管许多未满足的需求仍然存在。在这份共识声明中，作者总结了我们对MCC的理解的发展，同时也为未来的研究提供了共识建议。
Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer associated with advanced age and immunosuppression. Over the past decade, an association has been discovered between MCC and either integration of the Merkel cell polyomavirus, which likely drives tumorigenesis, or somatic mutations owing to ultraviolet-induced DNA damage. Both virus-positive and virus-negative MCCs are immunogenic, and inhibition of the programmed cell death protein 1 (PD-1)–programmed cell death 1 ligand 1 (PD-L1) immune checkpoint has proved to be highly effective in treating patients with metastatic MCC; however, not all patients have a durable response to immunotherapy. Despite these rapid advances in the understanding and management of patients with MCC, many basic, translational and clinical research questions remain unanswered. In March 2018, an International Workshop on Merkel Cell Carcinoma Research was held at the US National Cancer Institute, at which academic, government and industry experts met to identify the highest-priority research questions. Here, we review the biology and treatment of MCC and report the consensus-based recommendations agreed upon during the workshop. Merkel cell carcinoma (MCC) is a rare and aggressive form of nonmelanoma skin cancer. The availability of immune checkpoint inhibition has improved the outcomes of a subset of patients with MCC, although many unmet needs continue to exist. In this Consensus Statement, the authors summarize developments in our understanding of MCC while also providing consensus recommendations for future research.
登录
查看更多内容
影响因子：
6.7
作者：
Berrios C;Padi M;Keibler MA;Park DE;Molla V;Cheng J;Lee SM;Stephanopoulos G;Quackenbush J;DeCaprio JA
通讯作者：
DeCaprio JA
影响因子：
6.2
作者：
Andea, Aleodor A.;Coit, Daniel G.;Busam, Klaus J.
通讯作者：
Busam, Klaus J.
影响因子：
45.3
作者：
Davids, Matthew;Charlton, Amanda;Goh, Boon Cher
通讯作者：
Goh, Boon Cher
影响因子：
3.8
作者：
Buder, Kristina;Lapa, Constantin;Becker, Jurgen C.
通讯作者：
Becker, Jurgen C.
影响因子：
3.3
作者：
Andea, Aleodor A.;Patel, Raj;Siegal, Gene P.
通讯作者：
Siegal, Gene P.